Takeshi Isobe
Overview
Explore the profile of Takeshi Isobe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
1163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Furuya N, Tsubata Y, Hotta T, Yokoyama T, Yamasaki M, Ishikawa N, et al.
Cancer Med
. 2025 Jan;
14(1):e70568.
PMID: 39783855
Background: Cancer-associated thromboembolism has been thoroughly investigated in previous studies, and direct oral anticoagulants (DOACs) were established for the treatment and prevention of venous thromboembolism (VTE). However, the risks of...
2.
Nakashima K, Kodama H, Murakami H, Takahashi T, Kawakado K, Yanagawa T, et al.
Respir Investig
. 2024 Oct;
62(6):1137-1141.
PMID: 39366122
Background: There is a dearth of studies on the efficacy and safety of the tyrosine kinase inhibitors osimertinib (OSI) and gefitinib (GEF) in treating epidermal growth factor receptor (EGFR) mutation-positive...
3.
Kotani H, Han W, Iida Y, Tanino R, Katakawa K, Okimoto T, et al.
Cancers (Basel)
. 2024 Aug;
16(16).
PMID: 39199555
Background: Tyrosine kinase inhibitors (TKIs) inhibit receptor-mediated signals in cells. Axitinib is a TKI with high specificity for vascular endothelial growth factor receptors (VEGFRs). Aim: We determined whether axitinib could...
4.
Kono K, Nakashima K, Tsubata Y, Amano Y, Kawakado K, Yanagawa T, et al.
Thorac Cancer
. 2024 Jul;
15(22):1714-1717.
PMID: 38956899
A 61-year-old man presented to our hospital with a chief complaint of chronic cough. He was diagnosed with lung squamous cell carcinoma at clinical stage cT2aN3M1a. He received chemotherapy up...
5.
Kawakado K, Tsubata Y, Hotta T, Yamasaki M, Ishikawa N, Masuda T, et al.
Jpn J Clin Oncol
. 2024 May;
54(9):1032-1036.
PMID: 38769814
Objective: Cancer is a well-known risk factor for venous thromboembolism. The D-dimer level is used to predict venous thromboembolism; however, reports on an appropriate D-dimer cut-off value in Japanese patients...
6.
Ishikawa M, Nakamura K, Kawano R, Hayashi H, Ikeda T, Saito M, et al.
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672586
The usefulness of comprehensive genomic profiling (CGP) in the Japanese healthcare insurance system remains underexplored. Therefore, this large-scale study aimed to determine the usefulness of CGP in diagnosing digestive cancers....
7.
Okuno T, Isobe T, Tsubata Y
Clin Exp Metastasis
. 2024 Mar;
41(5):549-565.
PMID: 38466521
Lung cancer is a type of cancer that can metastasize to the lungs, brain, bones, liver, adrenal glands, and other organs; however, the occurrence of brain metastases is the most...
8.
Kawakado K, Tsubata Y, Hotta T, Yamasaki M, Ishikawa N, Fujitaka K, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38254791
Despite the occurrence of various hemorrhagic events during advanced lung cancer treatment, few researchers have reported on their risk factors. Moreover, the development of cancer-related thromboembolism indicates anticoagulant use. However,...
9.
Horie M, Nakashima K, Amano Y, Shiratsuki Y, Murakami K, Isobe T, et al.
Respir Med Case Rep
. 2024 Jan;
47:101976.
PMID: 38235162
Primary lung cancer with pulmonary alveolar proteinosis (PAP) is a rare condition. We present a case of a patient with primary lung cancer with PAP treated with an immune checkpoint...
10.
Nakashima K, Kitani K, Kono K, Yoshihara K, Kawakado K, Kobayashi M, et al.
Intern Med
. 2023 Dec;
63(15):2163-2166.
PMID: 38104995
A 71-year-old man with advanced lung adenocarcinoma was treated with carboplatin, pemetrexed, and pembrolizumab in June 2020. Pemetrexed and pembrolizumab maintenance therapy were continued until November 2022. A fever and...